Rad Source Technologies Introduces Premier X-Ray Blood Irradiator RS 3400 at MEDLAB Middle East 2021
|
By LabMedica International staff writers Posted on 22 Jun 2021 |

Image: X-Ray Blood Irradiator RS 3400 (Photo courtesy of Rad Source Technologies)
Rad Source Technologies (Buford, GA, USA), a supplier of commercial X-ray radiation products designed to replace self-shielded gamma irradiators, highlighted its newly redesigned RS 3400 Blood Irradiator at MEDLAB Middle East 2021.
Blood transfusion is a lifesaving procedure for people who are bleeding and people who cannot make a sufficient amount of blood on their own. A rare but almost always fatal complication from blood transfusion is called transfusion-associated graft-versus-host disease (TA-GVHD), where immune cells from the donor blood attack the recipient’s organs and cause a deadly infection that is nearly impossible to fight off.
Over 20 years ago, Rad Source pioneered the first-ever FDA-approved blood X-ray irradiation medical device used to prevent TA-GVHD, and has maintained its status as the industry leader and gold-standard in blood irradiation technology and instrumentation ever since. The company’s patented X-ray irradiation technology effectively and routinely inactivates the immune cells in donor blood, which diminishes the risk of developing TA-GVHD for the transfusion recipient.
The RS 3400 is the first FDA cleared blood irradiation device with the highest product throughput and volume available. It processes a variety of blood configurations of up to 6L capacity in 5 minutes - whole blood bags, platelet bags and loaded syringes in the same cycle. Combination of the patented Quastar X-ray emitter, rotating carousel, and new canister with support inserts may achieve as low as 1.5 DUR. Radiation safety features of the RS 3400 include redundant safety interlocks to prevent intrusion in to the radiation chamber while in operation. The unit is a cabinet X-ray device that has external emissions far below the federal standard for such devices.
Related Links:
Rad Source Technologies
Blood transfusion is a lifesaving procedure for people who are bleeding and people who cannot make a sufficient amount of blood on their own. A rare but almost always fatal complication from blood transfusion is called transfusion-associated graft-versus-host disease (TA-GVHD), where immune cells from the donor blood attack the recipient’s organs and cause a deadly infection that is nearly impossible to fight off.
Over 20 years ago, Rad Source pioneered the first-ever FDA-approved blood X-ray irradiation medical device used to prevent TA-GVHD, and has maintained its status as the industry leader and gold-standard in blood irradiation technology and instrumentation ever since. The company’s patented X-ray irradiation technology effectively and routinely inactivates the immune cells in donor blood, which diminishes the risk of developing TA-GVHD for the transfusion recipient.
The RS 3400 is the first FDA cleared blood irradiation device with the highest product throughput and volume available. It processes a variety of blood configurations of up to 6L capacity in 5 minutes - whole blood bags, platelet bags and loaded syringes in the same cycle. Combination of the patented Quastar X-ray emitter, rotating carousel, and new canister with support inserts may achieve as low as 1.5 DUR. Radiation safety features of the RS 3400 include redundant safety interlocks to prevent intrusion in to the radiation chamber while in operation. The unit is a cabinet X-ray device that has external emissions far below the federal standard for such devices.
Related Links:
Rad Source Technologies
Latest MEDLAB 2021 News
- Ortho Exhibits VITROS Range of Diagnostic Testing and Automation Solutions at MEDLAB Middle East 2021
- MP Biomedicals Exhibits Diagnostics Kits and Sample Prep Solutions at MEDLAB Middle East 2021
- BD Demonstrates Latest Medtech Innovations at MEDLAB Middle East 2021
- Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021
- Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021
- Horiba Medical Exhibits New Generation of Automated Hematology Analyzers at MEDLAB Middle East 2021
- Nova Biomedical Showcases Advanced Point-of-Care Capillary Blood Analyzers at MEDLAB Middle East 2021
- Erba Mannheim Showcases Exciting New Introductions at MEDLAB Middle East 2021
- Bioperfectus Presents Advanced Infectious Disease Diagnostic Solutions at MEDLAB Middle East 2021
- PerkinElmer Demonstrates High-Throughput MSMS Dried Blood Spot Screening Solutions at Medlab Middle East 2021
- PerkinElmer’s EUROIMMUN Presents Novel Ultrafast Automated Microscope and Intelligent Software for State-of-the-Art Diagnostics
- LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event
- Quidel Showcases Comprehensive Suite of COVID-19 Testing Solutions at MEDLAB Middle East 2021
- MEDLAB Middle East 2021 Brings World of Laboratory Medicine Together Under ‘United by Business’ Show Theme
Channels
Clinical Chemistry
view channel
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read moreMolecular Diagnostics
view channel
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read more
New Rapid Ebola Antigen Test Detects Infection at Point of Care
A serious Ebola epidemic centered in the Democratic Republic of the Congo has caused hundreds of deaths and triggered a global public health emergency, with cases also reported in Uganda.... Read more
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read more
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more









